Most Read Articles
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Antihypertensive drug discontinuation tied to increased AMI risk

05 Aug 2017

Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.

Researchers conducted a nested–control study including 1,245 patients hospitalized for their first AMI and 4,994 controls who had not been hospitalized. The risk of AMI was analysed by status of antihypertensive use: current users and discontinuers. Discontinuers were further divided into three according to the recency of discontinuation: recent discontinuers (≤90 days), intermediate-term discontinuers (91 to 180 days) and long-term discontinuers (>180 days).

Results showed that compared with current antihypertensive users, discontinuers were at significantly higher risk of developing AMI, regardless of time since discontinuation. The adjusted odds ratios were 1.54 (95 percent CI, 1.25 to 1.91; p<0.0005) with discontinuation of beta blockers, 2.25 (1.53 to 3.30; p<0.0005) with discontinuation of calcium channel blockers (CCBs) and 1.76 (1.24 to 2.48; p=0.002) with discontinuation of diuretics.

The risk of AMI further increased among long-term discontinuers (beta-blockers, CCBs, angiotensin-converting enzyme inhibitors and diuretics) and intermediate-term discontinuers (beta-blockers and CCBs) relative to current users.

No difference in AMI risk was observed between recent discontinuers and current users.

Researchers noted that the increased AMI risk after discontinuation of antihypertensive drugs is most likely a result of uncontrolled rebound hypertension in patients who discontinued their medications.

Other factors that may be involved include increases in myocardial oxygen requirements, sympathetic tone, circulating catecholamines, sensitivity of receptors to catecholamines, renin–angiotensin system activity, and platelet adhesiveness and aggregation, they added.

The present data underscore the importance of persistence to antihypertensive drug therapy to reduce the risk of AMI in patients with hypertension, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).